We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

89 hedge funds and large institutions have $114M invested in Clearside Biomedical in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 18 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 18

21% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 14

3% more funds holding

Funds holding: 86 → 89 (+3)

0.39% less ownership

Funds ownership: 4.25% → 3.86% (-0.39%)

35% less call options, than puts

Call options by funds: $455K | Put options by funds: $701K

48% less capital invested

Capital invested by funds: $218M → $114M (-$104M)

Holders
89
Holders Change
+3
Holders Change %
+3.49%
% of All Funds
2.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
34
Reduced
18
Closed
14
Calls
$455K
Puts
$701K
Net Calls
-$246K
Net Calls Change
+$439K

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$2.01M
2
AIC
AWM Investment Company
New York
+$1.67M
3
NC
Nexthera Capital
New York
+$1.43M
4
SI
Sofinnova Investments
California
+$1.38M
5
Two Sigma Investments
Two Sigma Investments
New York
+$754K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$16.3M
2
PA
Perceptive Advisors
New York
-$7.6M
3
CAM
Cormorant Asset Management
Massachusetts
-$6.34M
4
Millennium Management
Millennium Management
New York
-$2.75M
5
Invesco
Invesco
Georgia
-$1.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
USAA
26
United Services Automobile Association
Texas
$605K -$11.4K -96 -1%
Two Sigma Investments
27
Two Sigma Investments
New York
$585K +$754K +6,341 New
ECM
28
Endurant Capital Management
California
$580K +$514K +4,324 +221%
KCM
29
Kornitzer Capital Management
Kansas
$571K – – –
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$557K +$717K +6,035 New
Bank of New York Mellon
31
Bank of New York Mellon
New York
$519K +$30.1K +253 +5%
TCM
32
Tekla Capital Management
Massachusetts
$508K – – –
WS
33
Wedbush Securities
California
$465K +$599K +5,037 New
Charles Schwab
34
Charles Schwab
California
$371K – – –
Goldman Sachs
35
Goldman Sachs
New York
$371K +$207K +1,745 +77%
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
$366K +$471K +3,965 New
S
37
SignatureFD
Georgia
$359K +$407K +3,427 +743%
AA
38
ALPS Advisors
Colorado
$349K +$81.8K +688 +22%
PVI
39
Pura Vida Investments
New York
$311K +$401K +3,375 New
TA
40
Teachers Advisors
New York
$304K -$3.69K -31 -0.9%
TCIM
41
TIAA CREF Investment Management
New York
$295K -$364K -3,063 -49%
Jacobs Levy Equity Management
42
Jacobs Levy Equity Management
New Jersey
$282K +$364K +3,059 New
Lazard Asset Management
43
Lazard Asset Management
New York
$276K – – –
VEA
44
Virtus ETF Advisers
New York
$270K -$256K -2,150 -42%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$263K – – –
Renaissance Technologies
46
Renaissance Technologies
New York
$216K +$278K +2,340 New
EGM
47
Engineers Gate Manager
New York
$202K +$260K +2,191 New
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$197K – – –
FPC
49
Falcon Point Capital
California
$192K +$131K +1,102 +113%
TI
50
Trexquant Investment
Connecticut
$188K +$242K +2,036 New
1
2
3 4 5

CLSD Hedge Fund Activity: Q3 2018 in Review

89 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2018, worth a combined $114M — down 48% from $218M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CLSD positions and 14 closed out — a net gain of 3 holders — while 34 added to existing stakes and 18 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $2.01M. The largest seller was RA Capital Management, exiting entirely with an estimated $16.3M sold.

  • 89 institutional investors held Clearside Biomedical (CLSD) as of Q3 2018, up from 86 in Q2 2018.
  • Funds reported $114M of Clearside Biomedical stock for Q3 2018, down 48% quarter-over-quarter.
  • 17 funds opened new Clearside Biomedical positions in Q3 2018 and 14 closed out, a net change of +3 holders.
  • The largest Clearside Biomedical buyer in Q3 2018 was JP Morgan Chase, an estimated $2.01M added.
  • The largest Clearside Biomedical seller in Q3 2018 was RA Capital Management, an estimated $16.3M sold.

Based on aggregated 13F filings for Q3 2018.